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Adrenocortical tumors (ACT) in children are very rare and are most frequently diagnosed in
the context of the Li-Fraumeni syndrome, a multiple cancer syndrome linked to germline
mutations of the tumor suppressor geneTP53 with loss of heterozygosity in the tumors. A
peak of children ACT incidence is present in the states of southern Brazil, where they are
linked to the high prevalence in the population of a specificTP53 mutation (R337H). Children
ACT have specific features distinguishing them from adult tumors in their pathogenetic
mechanisms, genomic profiles, and prognosis. Epidemiological and molecular evidence
suggests that in most cases they are derived from the fetal adrenal.
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DYNAMICS OF HUMAN ADRENOCORTICAL MORPHOLOGY
AND HORMONE SECRETION DURING DEVELOPMENT AND
POSTNATAL LIFE
The adrenal gland is a continuously evolving endocrine organ
from the developmental to the elder age. In humans, adrenal gland
development begins at 3–4 weeks of gestation by a condensation of
the coelomic epithelium lining the abdominal cavity, followed at
4–6 weeks of gestation by proliferation and migration of coelomic
epithelial cells, and subsequent differentiation of fetal adrenal
cortical cells into two distinct zones (inner fetal zone and outer
definitive zone) at 8–10 weeks of gestation, while neural crest-
derived cells start to infiltrate the gland at 7–8 weeks of gestation
to give origin to adrenomedullary cells (1). Starting from around
the ninth week of gestation, the embryonal adrenal is surrounded
by the adrenal capsule formed by mesenchymal cells. Fetal adrenal
cells, which are large and rich in lipids, express the steroidogenic
enzyme CYP17, which enables them to produce high levels of
DHEA and its sulfoconjugate DHEAS, which play a key role for
the maintenance of pregnancy, being metabolized into estrogens
by the placenta (1, 2). By the end of the second trimester of gesta-
tion, a distinct zone (transitional zone) differentiates between the
definitive and fetal zones, which expressHSD3B2, this way starting
cortisol synthesis in the fetus. Close to birth,HSD3B2 is expressed
in the definitive zone, which acquires the capacity to synthesize
the mineralocorticoid hormone aldosterone. Cell proliferation in
the fetal adrenal is mainly localized in the outer definitive zone,
followed by centripetal migration and differentiation into fetal
zone cells, which subsequently die from apoptosis in the center of
the gland. This streaming process of adrenocortical cell differen-
tiation continues during the whole life, as shown by studies in the
mouse (3–5).
Starting shortly after birth, a rapid, dramatic remodeling of
adrenal cortex structure takes place, with massive shrinkage of the
gland due to apoptosis of the fetal zone and progressive differen-
tiation of the glomerulosa, fasciculata, and reticularis zona, which
are the hallmark of the adult adrenal (1). Defects in this process
may cause the cytomegalic form of adrenal hypoplasia congenita, a
syndrome of adrenal insufficiency due to altered postnatal adreno-
cortical differentiation due to mutations in the NR0B1 (DAX-1)
gene [reviewed in Ref. (6)]. Studies in pre-term neonates have
shown that parturition itself is the cause for fetal adrenal involu-
tion (7), suggesting a crosstalk between placenta and fetal adrenal
in reciprocal maintenance. Remarkably, postnatal adrenal remod-
eling also takes place in the mouse adrenal cortex, where an inner
zone adjacent to the medulla termed zone X, that lineage tracing
experiments have shown to be derived from the fetal adrenal (8),
regresses after puberty in males and after the first pregnancy in
females.
After being suppressed following the regression of the fetal
zone, adrenal production of DHEA/DHEAS starts to progressively
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increase again by around 8 years of age. This phenomenon is
termed adrenarche and is concomitant with full differentiation
of the reticularis zone, which expresses CYP17 but not HSD3B2.
Moreover, in the zona reticularis, CYP17 has an increased ratio
of 17,20-lyase to 17α hydroxylase activity (which favors DHEA
production) compared to the zona fasciculata, probably due to
increased serine phosphorylation and increased abundance of
cytochrome b5 (CYB5), which allosterically stimulates 17,20-lyase
activity of CYP17 (9). DHEA/DHEAS levels continue to increase
until adulthood and then progressively decline (adrenopause)
reaching pre-adrenarche levels by the ninth decade, correlating
with progressive atrophy of the zona reticularis (10).
ADRENOCORTICAL TUMORS IN CHILDREN AND ADULTS:
SIMILARITIES AND DIFFERENCES
Adrenocortical tumors (ACT) are among the most common neo-
plasms in humans and are frequently detected by hazard during
diagnostic procedures for other medical issues (incidentalomas),
in the great majority of cases remaining clinically silent and having
a completely benign prognosis. In contrast, adrenocortical malig-
nancies (adrenocortical carcinomas or ACC) are very rare, with
a general incidence of 0.7–2 cases/million/year, with a maximum
between 40 and 50 years of age and a higher frequency in women
than in men (11). They become clinically evident with signs and
symptoms due to hormone excess (Cushing’s syndrome, andro-
gen excess) and/or local symptoms (pain, abdominal discomfort).
The prognosis of ACC is still poor, with an average 5-year over-
all survival around 40%, which is influenced to a great extent
by tumor stage at diagnosis. Some histopathological parameters
(Weiss score≥3, Ki-67 index>10%) also have negative prognostic
value (11).
Adrenocortical tumors in children under 15 years of age are
even rarer. Their worldwide incidence has been estimated at
0.3/million/year with a bimodal peak under the age of 5 and after
10 years and they also affect girls more frequently than boys. The
main reason why ACT in children become clinically evident is vir-
ilization, which may be associated to Cushing’s syndrome. Overall
survival at 5 years after diagnosis in children with ACT is better
than in adult patients, approximating 50%. Favorable prognostic
factors are younger age (<4 years), stage I at diagnosis, tumor
weight ≤200 g, volume <200 cm3, and presence of virilization
alone (12). It is noteworthy that in children ACT, the Weiss score
is not a reliable system to assess malignancy (13–15) (Table 1).
Childhood malignancies have long been associated to con-
genital defects (16), which suggest that they may be considered
as a degeneration of normal developmental processes. Children
ACT are a typical example since they can be found in the context
of two genetically determined syndromes, Beckwith-Wiedemann
and Li-Fraumeni.
(1) Adrenocortical hyperplasia and neoplasms of variable malig-
nancy are common in Beckwith-Wiedemann syndrome, a
systemic overgrowth syndrome caused by genetic defects as
uniparental disomy in the 11p15 chromosomal region (17),
which cause overexpression of the IGF2 growth factor in the
great majority of cases. Loss of heterozygosity (LOH) of the
11p15 region is a systematic finding, not related to prognosis
(18–20), in children ACT, leading to IGF2 overexpression from
the paternal allele. Similarly, IGF2 is expressed at high levels
in the fetal adrenal where it has an important role to regulate
proliferation and steroid production (1). Conversely, IGF2
overexpression and abnormalities in the 11p15 region are a
marker of malignancy in ACT of adults (21, 22). In mouse
models, Igf2 overexpression in the adrenal induces tissue
hyperplasia but is not able to induce malignant tumorigenesis
per se (23, 24).
(2) Adrenocortical tumors are a distinctive feature of Li-Fraumeni
syndrome (LFS), a multiple cancer syndrome due to germline
mutations in theTP53 tumor suppressor gene [(25); reviewed
in Ref. (26)] encoding p53, a transcription factor that has
a pivotal role in preserving genome integrity and activating
apoptosis of cells bearing irreparable DNA damage (27). It
has been shown that in LFS, excessive DNA copy number
variation exists in the patients’ germline, which may predis-
pose to cancer (28). Due to its rarity and its characteristic
association with LFS, discovery of an ACT in a child is an
absolute indication for researching TP53 mutations in the
proband and in his/her parents as well indicative for genetic
counseling. Conversely, germline TP53 mutations are much
less common in adults with ACC (29, 30) (Table 1). The high
incidence of children ACT in LFS suggests that normal p53
function is required for the physiological process of post-
natal fetal adrenal regression (Figure 1). In the absence of
p53, genetic alterations may accumulate in the adrenal dri-
ving proliferation [such as NR5A1 overexpression, (31, 32);
see below section on Whole Genome Studies in Children and
Adult ACT Reveal Important Drivers for Tumorigenesis and
LOH of 11p15 leading to IGF2 overexpression (18–20)] of spe-
cific cellular clones. This increased proliferative capacity may
favor the emergence of further genetic alterations ultimately
leading to clonal expansion and tumorigenesis [reviewed in
Ref. (33)].
In classical LFS, due to TP53 mutations that completely abol-
ish protein function, the lifetime incidence of cancer in carriers
is close to 100%. However, low-penetrance mutated TP53 alle-
les exist that can increase the risk of developing cancer only in a
fraction of carriers (34). A remarkable example of that situation
exists in southern Brazil. In that geographical region, children
ACT prevalence is at least 15-fold higher than in the rest of the
world (10). This is related to a specific germline TP53 muta-
tion (R337H) (35, 36), whose prevalence is very high (0.3%) in
the population but whose penetrance to produce ACT in chil-
dren has been estimated at only about 2% (37). However, the
TP53 R337H mutation has also been reported to be associated
to other cancers in the Li-Fraumeni spectrum (38–41) and so
its overall penetrance is still unknown. R337 is a conserved argi-
nine residue in the C-terminal tetramerization domain of p53
whose mutation to histidine destabilizes p53 tetramer formation
in conditions of elevated temperature and pH (42). It has been
shown that a founder effect is responsible for the spreading of the
TP53 R337H mutation in the population of southern Brazil (43,
44). An about 0.5 Mb identical by descent haplotype in 17p13
encompassing the TP53 gene carrying the R337H mutation is
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Table 1 | Distinctive features and common characteristics of ACT in children and adults.
Children ACT Adult ACC References
Peak age at diagnosis 3–4 years 40–50 years; peak extending into the seventh
decade
(10, 11, 26)
Clinical presentation Most often virilization; may be associated
with Cushing’s syndrome
Cushing’s syndrome or hypertension; may be
associated with virilization
(10, 11)
Prevalence Worldwide: 0.3 cases/million/year;
southern Brazil: 3.4–4.2 cases/million/year
0.7–2/million/year for ACC (10, 11)
Most common genomic alterations 11p15 LOH; 9q34 gain; 4q34 loss Complex pattern (46, 70–74, 86–92)
Genetic syndromes
Overall LFS >50% Sporadic germline TP53 mutations (26, 29, 30)
Endemic germline TP53 R337H (Brazil) >93% <20% (10)
Beckwith-Wiedemann syndrome Yes Uncommon (17, 47)
FAP Uncommon Yes (47, 48)
MEN1 Uncommon Yes (47, 49)
Lynch syndrome Uncommon Yes (47, 50)
NF1 Uncommon Yes (47, 51)
Prognostic relevance of
Pathological (Weiss) score Low High (13–15)
Ki-67 index Unknown High (11)
Prognostic relevance of
TP53 mutations No (germline) Yes (somatic) (26, 29, 30)
IGF2 overexpression No Yes (18–22)
NOV down-regulation No Yes (19, 52)
SF-1 overexpression No Yes (31, 78, 81, 82)
HLA class II down-regulation Possible No (19, 22)
DLGAP5-PINK1 expression No Yes (54, 56)
BUB1B-PINK1 expression No Yes (54, 56)
Molecular pathways involved
IGF2 Yes Yes (18–22)
p53/Rb Yes (TP53 mutations) Yes (TP53/CDKN2A/RB1 mutations) (26, 57, 66, 85)
Beta-catenin Yes (CTNNB1 mutations) Yes (CTNNB1/ZNRF3 mutations) (57, 66, 85)
Chromatin remodeling Yes (ATRX mutations) Yes (MEN1/DAXX/ATRX/MED12/TERT
mutations)
(66, 85)
conserved in all carriers of the mutation (45, 46). A newborn
screening and surveillance program of the TP53 R337H muta-
tion carriers in the state of Paraná has proven to be successful to
detect ACT in children at an early stage and to treat it with bet-
ter therapeutic results compared to children who did not undergo
surveillance (37).
Apart from rare cases of germline TP53 mutations, as men-
tioned before (29, 30), ACC in adults may also be associated to
other hereditary conditions in some uncommon cases [reviewed
in Ref. (47)]: familial adenomatous polyposis (FAP) (48), mul-
tiple endocrine neoplasia type1 (MEN1) (49), Lynch syndrome
(50), and neurofibromatosis type 1 (NF1) (51) (Table 1).
GENOME-WIDE STUDIES IN CHILDREN AND ADULT ACT
DISTINCT PATTERNS OF CODING GENES EXPRESSION IN CHILDREN VS.
ADULT ACT
Children ACT can be readily differentiated from age-matched
normal adrenals by unsupervised clustering based on their gene
expression profiles (19). As reported before, IGF2 is the single
gene that is most highly up-regulated in children ACT, while genes
in the 11p15 region expressed from the maternal allele (KCNQ1,
CDKN1C) are among the most strongly down-regulated tran-
scripts. These data are consistent with the systematic LOH of
11p15 in those tumors, with conservation of the paternal allele
and loss of the maternal allele (18, 20). Genes belonging to growth
factor receptor and mitogen-activated kinase pathways are also
dysregulated in children ACT. This suggests that those signaling
pathways may be targets for therapeutic intervention. Further-
more, HSD3B2, a steroidogenic enzyme involved in the synthesis
of aldosterone and cortisol and expressed in the glomerulosa and
reticularis zones of the adult adrenal cortex and its transcrip-
tional regulators NR4A1 and NR4A2 are strongly down-regulated
in children ACT, lending further support to the hypothesis of their
derivation from the fetal adrenal. This is also suggested by the find-
ing that global gene expression profiles of children ACT are signif-
icantly correlated with those present in the fetal adrenal. Another
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FIGURE 1 | A hypothesis forTP53 role during physiological
adrenocortical remodeling in early postnatal life and pathogenesis of
children ACT. A window of sensitivity (with an early peak; shaded in grey) of
human adrenal to defective p53 function exists during the first years after
birth when its physiological involution takes place. Mutant p53 may favor
genomic instability, which in some cells may cause LOH of 11p15 and
gain/amplification of NR5A1, which confer those cells a selective advantage
for growth and lead to tumor formation. Additional genetic alterations arising
in this mutation-prone background may cause malignancy. Combined adrenal
weight is indicated with black circles. Relative adrenal weight in relationship
to body weight is indicated with white circles. Adapted in part from Ref. (1)
with permission from Endocrine Society Press.
strongly down-regulated gene in children ACT is NOV, encoding a
secreted multimodular protein that has a pro-apoptotic function
on adrenocortical cancer cells (52). In the study by West et al. (19),
a set of 52 differentially expressed genes between adrenocortical
adenomas and carcinomas (as distinguished by histological para-
meters) was identified. It is noteworthy that those included some
transcripts encoding HLA class II molecules. Down-regulation of
class II expression may represent a mechanism to escape immune
surveillance, which could contribute to malignancy. Since malig-
nancy markers are dramatically lacking for children ACT, it will be
very important to confirm those data in larger series of patients.
However, a recent immunohistochemical study failed to detect
consistent HLA class II immunoreactivity in children ACT, both
benign and malignant (53).
Unsupervised clustering of gene expression profiles of adult
ACT allowed to distinguish two groups, termed C1 and C2 in the
study by de Reyniès et al. (54). The C1 group could be further sub-
divided into C1A and C1B, which correspond to unfavorable and
favorable outcome, respectively. Those results were confirmed by
another independent study (55), which also confirmed that IGF2
overexpression is associated to malignancy in adult ACC. From
gene expression data, de Reyniès and collaborators identified both
a signature for malignancy based on the analysis of the expression
of two genes (DLGAP5/PINK1) and a two-gene (BUB1B/PINK1)
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molecular predictor of overall survival for patients with ACC (54).
Remarkably, those molecular markers were confirmed to be valid
prognostic indicators in adult but not in children ACT in a study
on patients from southern Brazil (56) (Table 1). Further studies
showed that tumors classified in the C1A group could be fur-
ther divided into two subgroups each one bearing either TP53 or
CTNNB1 (beta-catenin) mutations and in a third subgroup with
no other known mutation (57). The importance of the activation
of the beta-catenin pathway for adrenocortical tumorigenesis is
also shown by studies in mouse models [(23, 24, 58); reviewed in
Ref. (59)].
microRNA SETS DIFFERENTIALLY EXPRESSED IN CHILDREN AND
ADULT ACT
In the only study published to date investigating miRNA expres-
sion profiles in children ACT, a distinct subgroup of miRNA was
found to be differentially expressed in tumor samples compared to
age-matched normal adrenal cortex (60). This subgroup included
miR-99a and miR-100, which are down-regulated in children ACT
and are able to down-regulate expression of IGF-1R (the receptor
for IGF2), mTOR, and its associated protein raptor in adreno-
cortical cell lines. These proteins are up-regulated in children
ACT and their pharmacological blockade is able to significantly
decrease adrenocortical cancer cell proliferation (60–63). These
results show that miR-99a and miR-100 have an important role
in children ACT by the modulation of growth factor signaling
through the IGF-1R–mTOR pathway.
On the other hand, several studies reported data on miRNA
expression profiles in adult ACT. Those studies show in general
only limited overlap [reviewed in Ref. (64)]. Nevertheless, most
studies detected overexpression in ACC of miR-483-5p and/or -
3p, whose gene is situated in an intron of IGF2 and may have an
independent oncogenic function (65). miR-483-3p was also found
up-regulated in children ACT in the study by Doghman et al.
(60). Other miRNAs that display similar differential regulation
in children and adult ACT are miR-503 (up-regulated), miR-195,
miR-214, and miR-375 (down-regulated). A recently published
integrative analysis of genomic alterations in adult ACC (66) found
up-regulation of miRNAs belonging to themiR-506-514 cluster on
chromosome Xq27 and down-regulation of the expression of the
DLK1-MEG3miRNA cluster on chromosome 14q in one subgroup
of samples with favorable prognosis (C1B; see below section on
Whole Genome Studies in Children and Adult ACT Reveal Impor-
tant Drivers for Tumorigenesis). There is of great interest for the
potential use of circulating miRNAs as biomarkers of malignancy
in ACC (67–69).
WHOLE GENOME STUDIES IN CHILDREN AND ADULT ACT REVEAL
IMPORTANT DRIVERS FOR TUMORIGENESIS
The first studies analyzing children ACT genome copy num-
ber alterations by comparative genomic hybridization (CGH)
reported patterns of recurrent gains and losses (70–72). In par-
ticular, one of the most common alterations found in almost
all cases of children ACT investigated was the gain/amplification
of 9q34. Gains in this region were also reported in some stud-
ies of chromosomal alterations in adult ACT (73, 74). In close
proximity to this chromosomal region (9q33) is situated the gene
(NR5A1) encoding the transcription factor SF-1, a master regula-
tor of adrenocortical and gonadal development [reviewed in Ref.
(75, 76)]. Further studies showed that the NR5A1 gene is ampli-
fied and the SF-1 protein is overexpressed in the large majority of
Brazilian children ACT (31, 77, 78). Interestingly, the SF-1 protein
was overexpressed even in cases lacking gene amplification (31,
78), suggesting that mechanisms in addition to copy number gain
may also account for SF-1 overexpression. The dosage-dependent
effect of SF-1 in boosting adrenocortical cell proliferation was
shown by studies in human cell lines and in transgenic mice (32)
by regulation of a fairly large set of dosage-dependent target genes
far exceeding its classical steroidogenic targets [(79); reviewed in
Ref. (80)]. In children ACT, SF-1 overexpression appears to be a
widespread finding, with no relationship with malignancy [(31,
78); see Figure 1]. Conversely, SF-1 overexpression in adult ACT
is less common than in children (78) and is an unfavorable prog-
nostic marker (81, 82) (Table 1). Remarkably, SF-1 transcriptional
regulatory activity can be pharmacologically targeted leading to a
decrease of adrenocortical cancer cell proliferation (83), suggest-
ing that this transcription factor may represent a novel therapeutic
target in ACT.
A subsequent SNP array study on both Brazilian and
non-Brazilian ACT cases precisely defined recurrent genomic
alterations in children ACT (46), the most frequent being loss
of 4q34, gain of 9q33-q34 and 19p, and LOH of the whole
chromosome 17 (harboring TP53) and 11p15 (harboring IGF2).
Remarkably, a number of focal deletions were detected at 4q34,
defining a common deleted region surrounding the non-coding
RNA LINC00290 gene. It is also noteworthy that the extent of the
peak region of gain in 9q33-q34 suggests that other genes lying in
a telomeric position with respect to NR5A1 may also be impor-
tant for ACT pathogenesis. In addition, focal amplifications and
homozygous deletions comprising well-known oncogenes (MYC,
MDM2, PDGFRA, KIT, MCL1, BCL2L1) and tumor suppressors
(TP53, RB1, RPH3AL) were identified. Although genomic pro-
files in non-Brazilian tumors with a mutated TP53 (other than
R337H) were similar to Brazilian tumors, those with a wild-type
TP53 displayed distinct genomic alterations, harboring signifi-
cantly fewer rearrangements. Remarkably, 50% of TP53 wild-type
tumors investigated in this study displayed as sole rearrange-
ment a copy-neutral LOH of the imprinted region at 11p15,
providing further evidence for a major role of this region in ACT
development.
The landscape of genomic alterations in a worldwide series
of children ACT enrolled at IPACTR (84) has been more pre-
cisely defined by a very recent study integrating whole exome,
whole genome, and RNA-sequencing data (85). This work con-
firmed LOH in the 11p15 region in the large majority of cases
and systematic overexpression of IGF2, together with frequent
TP53 mutations, widespread 9q copy number gain, and 4q34 loss.
By comparing the mutant allele fraction of SNV in copy-neutral
LOH regions to allelic imbalance values, it was possible to estab-
lish that in most cases copy-neutral LOH of chromosomes 11p
and 17 occurred early during tumorigenesis, suggesting that those
events drive tumor formation. Additional recurrent genetic alter-
ations in children ACT were somatic mutations in the ATRX (a
DNA helicase) and CTNNB1 genes. Intriguingly, some tumors
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FIGURE 2 | Differences and similarities in genomic profiles between children and adult ACT. (A) Genomic alterations in children ACT. (B) Genomic
alterations in adult ACC. Common regions of gains (chr. 5, 9q, 19) and losses (chr. 11) are indicated with arrows. Adapted from Ref. (46, 91) with permission
from Endocrine Society Press.
bore integration of human herpesvirus-6 (HHV6) in the telom-
eric region of chromosome 11p. A poor outcome was predicted
by concomitant TP53/ATRX mutations and associated genomic
abnormalities, including massive structural variations and a high
background mutation rate (Table 1).
In adult ACT, earlier CGH studies showed a significantly
increased prevalence of genomic imbalances in carcinomas com-
pared to adenomas and sometimes contrasting patterns of gain
and losses (73, 74, 86–88). CGH array studies evidenced a set of
chromosomal aberrations in ACC associated with survival in a
fashion dependent on their accumulation (89). Carcinomas were
confirmed to harbor a higher number of chromosomal alterations
than adenomas (90–92). Recently, activating mutations of the
PKA catalytic subunit were shown to be associated with cortisol-
secreting adrenocortical adenomas in adults (93–96). In general,
gains had a higher impact than losses on gene expression profiles
(91). A comparison between genome alterations in children ACT
and adult ACC is shown in Figure 2. Methylome studies were also
performed in adult ACC (97–99). According to their DNA methy-
lation levels, malignant tumors could be divided into two groups,
one displaying low and the other one elevated levels of methylation
in CpG islands (CpG island methylator phenotype, CIMP). This
hypermethylated tumors group could in turn be subdivided into
two subgroups (CIMP-high and CIMP-low),which had prognostic
relevance, with the CIMP-high phenotype clearly being associated
to worse prognosis (99).
A study integrating transcriptome, miRNome, copy num-
ber alterations, methylome, and whole exome sequencing data
in adult ACC was recently published (66), showing that major
pathways involved by mutation or homozygous deletion include
beta-catenin (CTNNB1 and ZNRF3), p53/Rb signaling (TP53,
CDKN2A, and RB1), and chromatin remodeling (MEN1, DAXX,
ATRX, MED12, and TERT ) (Table 1). In addition, recurrent
homozygous deletions were found in 4q34, similarly to children
ACT. This study also showed that a substantial overlap exists
among the different omics classifications of ACC: the previously
identified gene expression profile clusters (C1A, C1B, and C2; see
section on Distinct Patterns of Coding Genes Expression in Children
vs. Adult ACT ) (54) are strongly correlated with subgroups based
on DNA methylation and miRNA expression, mutation rate, and
alteration of key molecular pathways.
PERSPECTIVES
Children ACT represent a distinct pathological entity compared
to tumors in adults concerning their origin, clinical manifesta-
tions, molecular alterations, and prognostic evolution. Important
fields of investigation in the future will be the search for genetic
and environmental factors that modulate penetrance of ACT in
carriers of germline TP53 mutations in order to orient screening
procedures to detect disease at an early stage, the identification of
robust biomarkers of malignancy, which are still lacking, and the
clinical testing of targeted therapies against the major molecular
pathways that are altered in this disease (100).
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